Celyad Oncology SA (EBR:CYAD)

Belgium flag Belgium · Delayed Price · Currency is EUR
0.4810
+0.0010 (0.21%)
Apr 25, 2025, 5:35 PM CET
50.31%
Market Cap 19.89M
Revenue (ttm) 186.00K
Net Income (ttm) -5.82M
Shares Out 41.43M
EPS (ttm) -0.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,480
Average Volume 39,381
Open 0.4760
Previous Close 0.4800
Day's Range 0.4760 - 0.5100
52-Week Range 0.2120 - 1.2200
Beta 1.24
RSI 45.88
Earnings Date Apr 4, 2025

About Celyad Oncology

Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies. It has licensing agreement wi... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 19
Stock Exchange Euronext Brussels
Ticker Symbol CYAD
Full Company Profile

Financial Performance

In 2024, Celyad Oncology's revenue was 186,000, an increase of 82.35% compared to the previous year's 102,000. Losses were -5.82 million, -31.06% less than in 2023.

Financial Statements

News

There is no news available yet.